214 related articles for article (PubMed ID: 30325210)
1. Making way for suppressing the FGF19/FGFR4 axis in cancer.
Prieto-Dominguez N; Shull AY; Teng Y
Future Med Chem; 2018 Oct; 10(20):2457-2470. PubMed ID: 30325210
[TBL] [Abstract][Full Text] [Related]
2. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
Lang L; Shull AY; Teng Y
Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750
[TBL] [Abstract][Full Text] [Related]
3. Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.
Zhou M; Wang X; Phung V; Lindhout DA; Mondal K; Hsu JY; Yang H; Humphrey M; Ding X; Arora T; Learned RM; DePaoli AM; Tian H; Ling L
Cancer Res; 2014 Jun; 74(12):3306-16. PubMed ID: 24728076
[TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.
Mellor HR
Liver Int; 2014 Jul; 34(6):e1-9. PubMed ID: 24393342
[TBL] [Abstract][Full Text] [Related]
5. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice.
Wu X; Ge H; Lemon B; Weiszmann J; Gupte J; Hawkins N; Li X; Tang J; Lindberg R; Li Y
Proc Natl Acad Sci U S A; 2009 Aug; 106(34):14379-84. PubMed ID: 19706524
[TBL] [Abstract][Full Text] [Related]
6. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways.
Wu AL; Coulter S; Liddle C; Wong A; Eastham-Anderson J; French DM; Peterson AS; Sonoda J
PLoS One; 2011 Mar; 6(3):e17868. PubMed ID: 21437243
[TBL] [Abstract][Full Text] [Related]
7. Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis.
Wu X; Li Y
Aging (Albany NY); 2009 Dec; 1(12):1023-7. PubMed ID: 20157585
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival.
Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO
Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118
[TBL] [Abstract][Full Text] [Related]
9. Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma.
Lin ZZ; Hsu C; Jeng YM; Hu FC; Pan HW; Wu YM; Hsu HC; Hu MC; Cheng AL
Liver Int; 2019 Sep; 39(9):1682-1691. PubMed ID: 30698907
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer.
Hu L; Cong L
Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668
[TBL] [Abstract][Full Text] [Related]
11. FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis.
Chen T; Liu H; Liu Z; Li K; Qin R; Wang Y; Liu J; Li Z; Gao Q; Pan C; Yang F; Zhao W; Zhang Z; Xu Y
Oncogene; 2021 Jul; 40(30):4941-4953. PubMed ID: 34163030
[TBL] [Abstract][Full Text] [Related]
12. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.
Yang C; Jin C; Li X; Wang F; McKeehan WL; Luo Y
PLoS One; 2012; 7(3):e33870. PubMed ID: 22442730
[TBL] [Abstract][Full Text] [Related]
13. FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression.
Zhao X; Xu F; Dominguez NP; Xiong Y; Xiong Z; Peng H; Shay C; Teng Y
Mol Carcinog; 2018 Nov; 57(11):1616-1625. PubMed ID: 30074276
[TBL] [Abstract][Full Text] [Related]
14. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
Gao L; Shay C; Lv F; Wang X; Teng Y
Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785
[TBL] [Abstract][Full Text] [Related]
15. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
16. FGF19/FGFR4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis.
Lang L; Xiong Y; Prieto-Dominguez N; Loveless R; Jensen C; Shay C; Teng Y
J Exp Clin Cancer Res; 2021 Mar; 40(1):93. PubMed ID: 33691750
[TBL] [Abstract][Full Text] [Related]
17. Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation.
Luo Y; Yang C; Lu W; Xie R; Jin C; Huang P; Wang F; McKeehan WL
J Biol Chem; 2010 Sep; 285(39):30069-78. PubMed ID: 20657013
[TBL] [Abstract][Full Text] [Related]
18. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y
J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043
[TBL] [Abstract][Full Text] [Related]
19. IL-1β inhibits β-Klotho expression and FGF19 signaling in hepatocytes.
Zhao Y; Meng C; Wang Y; Huang H; Liu W; Zhang JF; Zhao H; Feng B; Leung PS; Xia Y
Am J Physiol Endocrinol Metab; 2016 Feb; 310(4):E289-300. PubMed ID: 26670488
[TBL] [Abstract][Full Text] [Related]
20. Monomeric/dimeric forms of Fgf15/FGF19 show differential activity in hepatocyte proliferation and metabolic function.
Williams CM; Harper Calderon J; E H; Jimenez Y; Barringer K; Carbonaro M; Molina-Portela MDP; Thurston G; Li Z; Daly C
FASEB J; 2021 Feb; 35(2):e21286. PubMed ID: 33484478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
